Subject Index

A

Acarbose, non-insulin-dependent diabetes mellitus therapy, 793
Acquired immunodeficiency syndrome, acute diabetes onset symptoms, 1824
Adenosine, effect on insulin sensitivity of muscle, 1716
Adolescents
  adherence to diabetes regimen, 90
  insulin-dependent diabetes mellitus
    eating disorders, 1356, 1361
    self-care, 43
Adherence, measurement, 1658
Adults
  depression, 1631
  insulin-dependent diabetes mellitus, habitual physical activity, 1727
Advanced glycosylation end products
  diabetic complicagions, 1835
  nephropathy, 302
Alaskan Eskimos and Indians, prevalence of diabetes mellitus, 1390
Albumin excretion rate, insulin-dependent diabetes mellitus and pancreatic disease, 1591
Albuminuria, 1181
  abnormal, nephropathy development risk factor, 1192
Allergies, milk, mistaken for insulin allergy, 936
American Diabetes Association, duplicate publications, 1057, 1059, 1062
Amputation, lower-extremity, screening, 1386
Amputees, foot pressure, 905
Amylin, non-insulin-dependent diabetes mellitus pathogenesis, 297
Angiopathy, cell-cell interactions, 1168
Animals, use in research, ADA position statement, (Suppl. 2) 43
Anxiety, severe hypoglycemia, 518
Atherosclerotic
  carotid, prevalence, 1290
  cell-cell interactions, 1168
  lesion, 1156
  vascular disease, hyperglycemia, 1020
Atherosclerosis
  exercise effects, 1787
  premature, albuminuria, 1181
Autonomic nervous system, testing, 1095

B

Behavioral aspects, 1398
  eating disorders, 1402
  education evaluation, 1423
  overview, 1401
  stress, 1413
Bezold-Jarisch reflex, 309
Biguanides, non-insulin-dependent diabetes mellitus, 755
Bio-Rad capillary collection system, evaluation, 700
Biostator, data interpretation, 718
Blacks
  Americans, non-insulin-dependent diabetes mellitus, insulin action, 1295
  breast feeding, risk of insulin-dependent diabetes mellitus, 626
  South African women
    insulin receptor activity, 277
    plasma insulin and blood pressure, 556
Blood
  circulation, thermal biofeedback-assisted relaxation training, 853
  glucose monitoring, bedside in hospitals, ADA position statement, (Suppl. 2) 37
  pressure
    elevated, nephropathy development risk factor, 1192
    microalbuminuria, 1614
    non-insulin-dependent diabetes mellitus, insulin therapy effects, 1258
    relationship to plasma insulin, 556
  subcutaneous flow, relationship to rate of insulin absorption, 1484
Body fat distribution, non-insulin-dependent diabetes mellitus, 306
Brazil, prevalence of diabetes mellitus, 1509
Bulgaria, incidence of diabetes, 930

C

C-peptide
  response to
    meal stimulus, non-insulin-dependent diabettes mellitus, 1335
    pancreatic insulin content, 937
  secretion, insulin-dependent diabetes mellitus, prediction factors, 997
Capillary collection system, evaluation of Bio-Rad, 700
Capsaicin, effect on neuropathy, 8, 159
  sensory function, 15
  topical, improvement of symptoms, 1434
Cardiorespiratory fitness, mortality risk, 184
Cardiovascular
  autonomic nerve dysfunction, insulin-dependent diabetes mellitus, 908
  disease
    children, prediction, 244
    mortality, relationship to hyperglycemia, 1328
    risk factors
      epidemiology, 1141
      impaired glucose tolerance, 239
      physical activity, 236
      prevention/treatment of macrovascular disease, ADA consensus statement, (Suppl. 2) 68
    therapy, magnesium supplementation, 835
Case management, (Suppl. 1) 59
Cassava toxicity, not cause of diabetes mellitus, 1378
Catecholamines
  effects on insulin sensitivity of muscle, 1716
  response to hypoglycemia, 261
β-cells
  deterioration, insulin-dependent diabetes mellitus, 1009
  dysfunction, chronic hyperglycemia, 442
Central nervous system, somatosensory conduction delay, 532
Certified diabetes educators, assistance by industry representatives, 549
Children
  cardiovascular disease, prediction, 244
  growth before onset of diabetes mellitus, 1393
  insulin-dependent diabetes mellitus
    glycemic control effect on growth velocity, 826
    growth hormone, 490
    hyperglycemia effect on nerve conduction, 502
    incidence, Russia, 915
    insulinlike growth factor I, 490
    outpatient management, 95
    self-care, 43
    Sudan, 1556
  ketoacidosis, management, 141
  non-insulin-dependent diabetes mellitus prediction, 244
China, glucose tolerance test, criteria assessment, 988
Cholesterol
  HDL, 282
    pancreas-kidney transplantation, 35
    reduced, detection and management, 1068
  LDL, pancreas-kidney transplantation, 35
Chronic renal failure, lipoprotein(a) levels, 976
Clinical Laboratory Improvement Amendments 1988, 1814

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Subject Index

A

Acarbose, non-insulin-dependent diabetes mellitus therapy, 793
Acquired immunodeficiency syndrome, acute diabetes onset symptoms, 1824
Adenosine, effect on insulin sensitivity of muscle, 1716
Adolescents
  adherence to diabetes regimen, 90
  insulin-dependent diabetes mellitus
    eating disorders, 1356, 1361
    self-care, 43
Adherence, measurement, 1658
Adults
  depression, 1631
  insulin-dependent diabetes mellitus, habitual physical activity, 1727
Advanced glycosylation end products
  diabetic complicagions, 1835
  nephropathy, 302
Alaskan Eskimos and Indians, prevalence of diabetes mellitus, 1390
Albumin excretion rate, insulin-dependent diabetes mellitus and pancreatic disease, 1591
Albuminuria, 1181
  abnormal, nephropathy development risk factor, 1192
Allergies, milk, mistaken for insulin allergy, 936
American Diabetes Association, duplicate publications, 1057, 1059, 1062
Amputation, lower-extremity, screening, 1386
Amputees, foot pressure, 905
Amylin, non-insulin-dependent diabetes mellitus pathogenesis, 297
Angiopathy, cell-cell interactions, 1168
Animals, use in research, ADA position statement, (Suppl. 2) 43
Anxiety, severe hypoglycemia, 518
Atherosclerotic
  carotid, prevalence, 1290
  cell-cell interactions, 1168
  lesion, 1156
  vascular disease, hyperglycemia, 1020
Atherosclerosis
  exercise effects, 1787
  premature, albuminuria, 1181
Autonomic nervous system, testing, 1095

B

Behavioral aspects, 1398
  eating disorders, 1402
  education evaluation, 1423
  overview, 1401
  stress, 1413
Bezold-Jarisch reflex, 309
Biguanides, non-insulin-dependent diabetes mellitus, 755
Bio-Rad capillary collection system, evaluation, 700
Biostator, data interpretation, 718
Blacks
  Americans, non-insulin-dependent diabetes mellitus, insulin action, 1295
  breast feeding, risk of insulin-dependent diabetes mellitus, 626
  South African women
    insulin receptor activity, 277
    plasma insulin and blood pressure, 556
Blood
  circulation, thermal biofeedback-assisted relaxation training, 853
  glucose monitoring, bedside in hospitals, ADA position statement, (Suppl. 2) 37
  pressure
    elevated, nephropathy development risk factor, 1192
    microalbuminuria, 1614
    non-insulin-dependent diabetes mellitus, insulin therapy effects, 1258
    relationship to plasma insulin, 556
  subcutaneous flow, relationship to rate of insulin absorption, 1484
Body fat distribution, non-insulin-dependent diabetes mellitus, 306
Brazil, prevalence of diabetes mellitus, 1509
Bulgaria, incidence of diabetes, 930

C

C-peptide
  response to
    meal stimulus, non-insulin-dependent diabettes mellitus, 1335
    pancreatic insulin content, 937
  secretion, insulin-dependent diabetes mellitus, prediction factors, 997
Capillary collection system, evaluation of Bio-Rad, 700
Capsaicin, effect on neuropathy, 8, 159
  sensory function, 15
  topical, improvement of symptoms, 1434
Cardiorespiratory fitness, mortality risk, 184
Cardiovascular
  autonomic nerve dysfunction, insulin-dependent diabetes mellitus, 908
  disease
    children, prediction, 244
    mortality, relationship to hyperglycemia, 1328
    risk factors
      epidemiology, 1141
      impaired glucose tolerance, 239
      physical activity, 236
      prevention/treatment of macrovascular disease, ADA consensus statement, (Suppl. 2) 68
    therapy, magnesium supplementation, 835
Case management, (Suppl. 1) 59
Cassava toxicity, not cause of diabetes mellitus, 1378
Catecholamines
  effects on insulin sensitivity of muscle, 1716
  response to hypoglycemia, 261
β-cells
  deterioration, insulin-dependent diabetes mellitus, 1009
  dysfunction, chronic hyperglycemia, 442
Central nervous system, somatosensory conduction delay, 532
Certified diabetes educators, assistance by industry representatives, 549
Children
  cardiovascular disease, prediction, 244
  growth before onset of diabetes mellitus, 1393
  insulin-dependent diabetes mellitus
    glycemic control effect on growth velocity, 826
    growth hormone, 490
    hyperglycemia effect on nerve conduction, 502
    incidence, Russia, 915
    insulinlike growth factor I, 490
    outpatient management, 95
    self-care, 43
    Sudan, 1556
  ketoacidosis, management, 141
  non-insulin-dependent diabetes mellitus prediction, 244
China, glucose tolerance test, criteria assessment, 988
Cholesterol
  HDL, 282
    pancreas-kidney transplantation, 35
    reduced, detection and management, 1068
  LDL, pancreas-kidney transplantation, 35
Chronic renal failure, lipoprotein(a) levels, 976
Clinical Laboratory Improvement Amendments 1988, 1814

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Combination therapy
biosynthetic human insulin and glyburide, 265
glyburide and biosynthetic human insulin, 265
insulin and metformin, 766
insulin and sulfonylurea, 746, 831, 953
metformin and sulfonylurea, 766
Computer applications and uses
glucose clamps, Biostator, 718
HMO data bases, pharmacy resources, 870
modem access, glycemic control, 971
patient education, diet, 204
simulations, insulin dose adjustment, 221
Concurrent care, ADA position statement, (Suppl. 2) 39
Congenital malformations, sonograms, 613
Continuous subcutaneous insulin infusion
ADA position statement, (Suppl. 2) 34
catheter obstruction, effect of insulin concentration, 593
exercise habits, 1727
Contraception, insulin-dependent diabetes mellitus, 1585
Coronary
artery disease, autonomic neuropathy, 288
heart disease
incidence, non-insulin-dependent diabetes mellitus, 820
mortality, relationship to hyperglycemia, 1328
risk factors, 1141
Correctional institutions, management of diabetes mellitus, ADA position statement, (Suppl. 2) 42
Corynebacteria, prevalence of in foot infections, 1531
Creatinine clearance, estimation of glomerular filtration rate, 609
CSII. *See* Continuous subcutaneous insulin infusion

D

Dawn phenomenon, 928
Department of Veterans Affairs, study on implanted insulin pump, 567
Depression
adults, 1631
insulin-dependent diabetes mellitus, 166
non-insulin-dependent diabetes mellitus, obesity, 253
Diabetes/diabetic complications, trends, 960
Diabetes Impact Management Scales, 469
Diabetic camp
prediabetes screening, 1439
stress management, 310
Diabetic ketoacidosis. *See* Ketoacidosis
Diabetic nephropathy. *See* Nephropathy
Diabetic retinopathy. *See* Retinopathy
Diabeto, evaluation, 204
Diagnosis of diabetes mellitus, (Suppl. 2) 4
Dialysis, 1226
Dichloroacetate, 785
Diet
education, computer-assisted, 204
fat, alterations and effect on glycemic control, 1499
food labeling regulations, 571
ADA position statement, (Suppl. 2) 45
fructose, chronic consumption effects, 1468
fruit juices, gestational diabetes, 1115
high carbohydrate intake, effect on hyperglycemia, 1572
infant nutrition, race, 626
low-glycemic index, benefits of, 562
noncaloric sweeteners, ADA position statement, (Suppl. 2) 29
non-insulin-dependent diabetes mellitus risk factor, 238
nutritional recommendations, ADA position statement, (Suppl. 2) 21
postprandial blood glucose levels, 522
protein intake, proteinuria, 178
purified cellulose, 111
soft drinks, 933
soya fibers, 111
starch, miglitol effects, 478
therapy, 1821
very-low-calorie, 293
wine, glycemic control, 546
Diphtheroids (*Corynebacteria*), prevalence in foot infections, 1531
Driving, commercial motor vehicles, policy variability, 1464
Dropout and relapse factors, 1477
Dyslipidemia
control of via glycemic control, 638
detection and management, 1068
non-insulin-dependent diabetes mellitus
effect on glycemic control, 508
prevalence, 1285

E

Early-onset, remission, nicotinamide, 121
Eating disorders
insulin-dependent diabetes mellitus, 1402
adolescents, 1356, 1361
interventions, 1643
Elderly
glucose-induced insulin secretion, 1
non-insulin-dependent diabetes mellitus, glyburide and glipizide effects, 75
use of premixed insulin, 1628
Employment and hypoglycemia, ADA position statement, (Suppl. 2) 44
Empowerment, patient, 922
Enalapril, hypoglycemia, 934
Endothelial cells, incidence of in retinopathy, 552
Endolethin, increased in non-insulin-dependent diabetes mellitus with retinopathy, 1396
β-endorphin levels in diabetes mellitus, 590
Erythrocyte spermidine levels, nephropathy and retinopathy, 543
Ethnic heterogeneity, lack of, insulin-dependent diabetes mellitus, 1303
Exercise
ADA position statement, (Suppl. 2) 36
atherosclerosis, effect on, 1787
glucoregulation, 1747, 1767
insulin
secretion, 1712
sensitivity, 1690, 1716
insulin-dependent diabetes mellitus
fuel/fluid homeostasis, 1736
glucose turnover, 1721
hypoglycemia prevention, 1732
intensive insulin therapy, habitual physical activity, 1727
platelet function increase, 1742
International Diabetic Athlets Association, history, 1811
life-style modification program, 1800
metabolic responses, 1767
muscle
blood flow, 693
interaction with insulin on glucose transport, 1679
skeletal, effects on metaboism, 1701
soleus, glucose metabolism, 1694
non-insulin-dependent diabetes mellitus, 136
ADA technical review, (Suppl. 2) 50
interaction with insulin, 1777
obesity, 1783
prevention, 1794
prolonged, fibrinolytic system response, 991
Eyes
care
benefits of retinopathy screening, 580
financial implications, (Suppl. 1) 32
refractory changes during non-insulin-dependent diabetes mellitus treatment, 938
See also Retinopathy

F

Fatty acid oxidation inhibitors, 773
Feet
care
ADA position statement, (Suppl. 2) 19
financial implications, (Suppl. 1) 29
infections, prevalence of *Corynebacteria*, 1531
pressure, amputees, 905
ulcers
healing, 1433, 1598
leukocyte scanning superior to magnetic resonance imaging, 1527
Fetal growth
delay, sonograms, 613

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

macrosomia, glycemic control, 1251
Fibrinogen, elevated, cardiovascular disease risk factor, 1245
Fibrinolytic system, response to prolonged exercise, 991
Financing health care, (Suppl. 1) 1
  conference issues and recommendations, (Suppl. 1) 66
  diabetic eye disease, (Suppl. 1) 32
  foot care, (Suppl. 1) 29
  health maintenance organizations, (Suppl. 1) 44
  Medicare
    admissions criteria (Florida), (Suppl. 1) 54
    payment under fee schedule, (Suppl. 1) 62
  patient education programs, (Suppl. 1) 36, 41
  pregnancy, (Suppl. 1) 22
  third-party payment, (Suppl. 1) 10
Food labeling
  ADA position statement, (Suppl. 2) 45
  regulations, 571
Fructose, chronic dietary consumption effects, 1468

G

Gangrene, osteomyelitis detection by scintigraphy, 1014
Gemfibrozil, effect on non-insulin-dependent diabetes mellitus lipoproteins, 146
Genetics
  albuminuria, 1181
  mutation, maturity-onset diabetes of the young, 1108
  non-insulin-dependent diabetes mellitus
    overview, 369
    risk factor, 237
Gestational diabetes mellitus, 716
  insulin requirements in final month, 1323
  ADA position statement, (Suppl. 2) 5
  fruit juices, 1115
  ketoacidosis, 968
  primary care physicians, 101
  screening, prediction of birth weight, 1605
  See also Pregnancy
Glibenclamide, combination therapy with insulin, 831
Glipizide, non-insulin-dependent diabetes mellitus, elderly, 75
Glomerular filtration rate, nephropathy, estimation, 609
Glucagonlike peptide I(7-37), 270, 1440, 1441
Glucagon
  secretion, insulin effects, 59
  test, hazard of, 1437
Glucose
  absorption, hypoglycemia effects, 1264
  effect on insulin secretion, 1
  homeostasis, 371
  impaired tolerance, prevalence in Brazil, 1509
  intolerance
    diagnosis of, (Suppl. 2) 4
    impaired insulin secretion, 1517
    insulin receptor activity, 277
    isolated fatty change of liver, marker, 1438
    prevalence, India, 1348
  levels, exercise effects, 1712
  metabolism
    exercise, soleus muscle, 1694
    menstrual cycle, 213
  monitoring, quality control, 1824
  pregnancy, fasting vs. postprandial, 1251
  regulation, 1747, 1767
  tolerance test
    criteria assessment, Chinese patients, 988
    oral, pregnancy, 18265, 1827
  transport
    insulin and exercise interaction in muscle, 1679
    non-insulin-dependent diabetes mellitus, overview, 396
  turnover, exercise effects, 1721
  utilization, diabetes effects, 1747
α-glucosidase inhibitors
  miglitol, effects on starch, 478
  non-insulin-dependent diabetes mellitus therapy, 793
Glutamate decarboxylase, insulin-dependent diabetes mellitus prediction, 132
Glutamic acid decarboxylase autoantibodies, islet cell antibodies, differences between, 1345
Glutamine metabolism, 1716
Glutathione, insulin secretion, 1
Glyburide
  combination therapy, 265
  hyperinsulinemia reduction, 719
  non-insulin-dependent diabetes mellitus, elderly, 75
  response in non-insulin-dependent diabetes mellitus, 696
Glycemia
  postprandial, soya and cellulose fibers, 111
  women, greater effect on hypertension, 1277
Glycemic control
  control of dyslipidemia, 638
  dietary fat alterations, short term effects, 1499
  early insulin-dependent diabetes mellitus, 980
  effect on growth velocity in children, 826
  effects of obesity, dyslipidemia, hypertension, 508
  implantable pumps, programmable, 19
  measurement of glycosylated hemoglobin, evaluation, 1045
  modem-based patient monitoring, 971
  monitoring, glycosylated serum protein levels, 645
  non-insulin-dependent diabetes mellitus
    insulin therapy effects, 27
    management of, 1560
  pregnancy, macrosomia, 1251
  relationship to diabetic complications, 1126
  stress management, 842
  wine consumption, 546
Glycemic index vs. glycemic response, nonsynonymous terms, 1436
Glycosylated
  hemoglobin, measurement
    device evaluation, 1045
    filter paper accuracy, 108
  serum protein levels, monitoring of glycemic control, 645
Growth
  children, before onset of diabetes mellitus, 1393
  hormone, insulin-dependent diabetes mellitus, children, 490
  velocity, effect of glycemic control in children, 826

H

HbA_{1c} measurement, evaluation of new method, 1494
Health care
  concurrent care, ADA position statement, (Suppl. 2) 39
  dropout and relapse factors, 1477
  financing, (Suppl. 1) 1
  hospital admission guidelines, ADA position statement, (Suppl. 2) 40
  professionals,
  diabetes attitudes and beliefs, 859
  quality of care, (Suppl. 1) 59
  standards of care, (Suppl. 1) 10
    ADA position statement, (Suppl. 2) 10
Health maintenance organizations
  data bases, pharmacy resources, 870
  history, (Suppl. 1) 44
Helsinki Heart Study, coronary heart disease incidence, non-insulin-dependent diabetes mellitus, 820
Hispanics, lack of ethnic heterogeneity, insulin-dependent diabetes mellitus, 1303
HMO. *See* Health maintenance organizations
"Honeymoon period," 66
Hospital admission guidelines, ADA position statement, (Suppl. 2) 40
Hyperfibrinogenemia, 1245
Hyperfiltration, glomerular, 142
Hyperglycemia
  atherosclerotic vascular disease, 1020
  cardiovascular disease, 1141
  children, effect on nerve conduction, 502
  chronic, β-cell dysfunction, 442
  fasting
    long-acting zinc insulin, 173
    twice-daily humulin ultralente insulin, 1031

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

non-insulin-dependent diabetes mellitus
high carbohydrate intake effects, 1572
overview, 331
prevalence, Saudi Arabia, 484
relationship to coronary/cardiovascular mortality, 1328
sulfonylureas, 741
tissue damage, 1126
young adults, effect on nerve conduction, 502
Hyperinsulinemia
atherosclerosis, 1156
predictor of non-insulin-dependent diabetes mellitus, 241
reduction by glyburide, 719
Hyperproinsulinemia, non-insulin-dependent diabetes mellitus, 723
Hypertension
antihypertensive therapy, 918
non-insulin-dependent diabetes mellitus, effect on glycemic control, 508
retinopathy risk factor, 1002
women, greater effect of glycemia, 1277
Hypertriglyceridemia
detection and management, 1068
prevalence, impaired glucose tolerance, 657
Hypoglycemia
catecholamine response, 261
employment, ADA position statement, (Suppl. 2) 44
enalapril-induced, 934
fatty acid oxidation inhibitors, 773
glucose absorption, 1264
human vs. animal insulin, 1110
insulin-dependent diabetes mellitus
exercise, 1732
pregnancy, 1034
insulin effect on glucagon secretion, 59
long-term neurological consequences, 583
pregnancy, hemodynamic states, 939
severe
anxiety, 518
frequency, 582

I

IDDM. *See* Insulin-dependent diabetes mellitus
Impaired glucose tolerance
cardiovascular disease, 239
glutathione effects, 1
hypertriglyceridemia, 657
Navajo Indians, 114
Tanzania, 1114
Implantable pumps. *See* Insulin therapy, implantable pumps
Incidence
Bulgaria, 930
insulin-dependent diabetes mellitus
children in Western Australia, 515
pregnancy, hypoglycemia, 1034
Russian children, 915
Sardinia, 1317
variation in New Zealand, 895
non-insulin-dependent diabetes mellitus
coronary heart disease, 820
retinopathy, Oklahoma Indians, 1620
India, glucose intolerance prevalence, 1348
Insulin
absorption rate, relationship to subcutaneous blood flow, 1484
action
Black Americans, non-insulin-dependent diabetes mellitus, 1295
insulin secretion, 335
allergy, milk allergy mistaken for, 936
antibodies
effect on insulin resistance in malnutrition-related diabetes, 721
human insulin effects, 124
Dawn phenomenon, 928
human
biosynthetic, 666
effect on insulin binding antibody production, 124
vs. animal, 585, 1110
hypoglycemia, effect on glucagon secretion, 59
interaction with exercise
glucose transport in muscle, 1679
non-insulin-dependent diabetes mellitus, 1777
levels, postprandial, 522
metabolic response to, 702
morning/bedtime NPH, combination therapy with sulfonylurea, 831
pancreatic, C-peptide response, 937
plasma, relationship to blood pressure, 556
premixed, use by elderly, 1628
receptor gene, mutations, 590
receptors
activity level, obesity and glusose intolerance, 277
defect, insulin resistance, 651
resistance
atherosclerosis, 1156
Black Americans, obesity, 1295
cardiovascular disease, 239, 1141
insulin receptor defect, 651
malnutrition-related diabetes, insulin antibodies, 721
metabolic response to insulin, 702
non-insulin-dependent diabetes mellitus, overview, 324, 337, 343
oral hypoglycemic agents, CS-045, 193
skeletal muscles, 418
secretion
exercise effects, 1712
glucose-induced, 1
impaired, glucose intolerance, 1517
insulin action, 335
non-insulin-dependent diabetes mellitus, overview, 319
sulfonylureas, 738, 1534
sensitivity, exercise effects, 1690
storage and injection recommendation, 1113
usage, commercial motor vehicle drivers, 1464
Insulin-dependent diabetes mellitus
adolescents
adherence to diabetes regimen, 90
eating disorders, 1356, 1361
self-care, 43
albumin excretion rate, pancreatic disease, 1591
albuminuria, 1181
β-cell deterioration, 1009
β-endorphin levels, 590
C-peptide secretion, prediction factors, 997
cardiovascular autonomic nerve dysfunction, 908
children
glycemic control effect on growth velocity, 826
growth hormone, 490
hyperglycemia effect on nerve conduction, 502
incidence, Russia, 915
insulinlike growth factor I, 490
outpatient management, 95
prediction, 128
self-care, 43
Sudan, 1556
chronic renal failure, lipoprotein(a) levels, 976
diet
fat alterations, effect on glycemic control, 1499
infant nutrition and race, 626
eating disorders, 1356, 1361, 1402
epidemiology, 137
ethnic heterogeneity, lack of, 1303
exercise
fibrinolytic system response to prolonged, 991
fuel/fluid homeostasis, 1736
glucose turnover, 1721
hypoglycemia prevention, 1732
platelet function increase, 1742
families of children/adolescents, use of SMBG test results, 1041
genetic marker, 705
glycemic control, 980
modem-based patient monitoring, 971
glycosylated hemoglobin, measurement, 108
health status measurement, 469
"honeymoon period," 66
hyperglycemia, long-acting zinc insulin, 173
hypoglycemia
catecholamines, 261
insulin effect on glucagon secretion, 59
prevention during exercise, 1732
severe, anxiety, 518
implantable pumps, programmable, 19
incidence
children in Western Australia, 515
Russian children, 915
Sardinia, 1317
variation in New Zealand, 895
insulin therapy

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

implantable pumps vs. subcutaneous insulin, 53
intensive, habitual physical activity, 1727
limited joint mobility, sorbinil effects, 588
lipid/lipoprotein levels, 886
microalbuminuria, plasma endothelin level, 1038
mortality, international comparisons, (Suppl. 1) 15
nephropathy, erythrocyte spermidine levels, 543
nitrate levels in community drinking waters, 1505
pancreas-kidney transplantation, lipids, 35
prediction, 140
children, 128
glutamate decarboxylase, 132
standardized intravenous glucose tolerance test, 1313
pregnancy, hypoglycemia incidence, 1034
prevalence
microalbuminuria, 495
Nigerian Igbo schoolchildren, 1310
prevention, ADA position statement, (Suppl. 2) 14
proinsulin levels, first-degree relatives, 632
psychosocial factors, 166
remission, 66
nicotinamide, 121
retinopathy, erythrocyte spermidine levels, 543
sex concordance, secondary attack rate, 559
smoking, morbidity, 947
visual system contrast sensitivity, 620
women
contraception, 1585
menstrual cycle, 213
young adults, hyperglycemia effect on nerve conduction, 502
Insulin therapy
administration, ADA position statement, (Suppl. 2) 30
combined with sulfonylurea, 746, 831, 953
dichloroacetate, 785
dose adjustment, computer simulation, 221
fasting hyperglycemia, zinc insulin, 173
implantable pumps
comparison to subcutaneous insulin therapy, 53
Department of Veterans Affairs study, 567
infection prevention, 1449
programmable, 19
trial results, 877
jet injectors, ADA technical review, (Suppl. 2) 48
non-insulin-dependent diabetes mellitus, effect on blood pressure, 1258
storage and injection recommendation, 1113
subcutaneous, compared to intraperitoneal implantable pumps, 53
twice-daily humulin ultralente, fasting hyperglycemia, 1031
two- and four-dose regimens, glycemic control, 27
Insulinlike growth factor I, insulin-dependent diabetes mellitus, children, 490
Interferon, retinoapthy treatment, 300
International Diabetic Athletes Association, history, 1811
Intravenous glucose tolerance test
comparison of two methods, 1053
standardization to predict insulin-dependent diabetes mellitus, 1313
Islet cell antibodies
insulin-dependent diabetes mellitus, first-degree relatives, 632
glutamic acid decarboxylase antibodies, differences between, 1345

J

Japan, children, lipoprotein(a), 1112

K

Ketoacidosis
children, management, 141
gestational diabetes mellitus, 968
Kidney
function, pancreatic disease, 1591
transplantation, quality of life, 305, 1459

L

Laboratory practice, federal regulation, 1814
Leukocytes
ROI generation, non-insulin-dependent diabetes mellitus, 1050
scanning superior to magnetic resonance imaging in foot ulcers, 1527
Lipids
disorders, detection and management, 1068
level in insulin-dependent diabetes mellitus, 886
pancreas-kidney transplantation, 35
Lipoproteins
chronic dietary fructose consumption effects, 1468
high carbohydrate intake effects, 1572
level in insulin-dependent diabetes mellitus, 886
Lipoprotein(a)
intermediate-density, gemfibrozil effects, 146
Japanese children, 1112
levels
chronic renal failure, 976
metabolic control, 941, 1441
triglyceride-rich, implantable pumps, programmable, 19
Liver
isolated fatty change, marker of glucose intolerance, 1438
role in non-insulin-dependent diabetes mellitus pathophysiology, 431

M

Magnesium
deficiency, non-insulin-dependent diabetes mellitus
enchanced platelet reactivity, 835
intracellular, 1825
supplementation, 1065
cardiovascular disease therapy, 835
Malignant otitis externa, treatment, 1826
Maturity-onset diabetes of the young, genetic mutation, 1108
Medicare
admission criteria (Florida), (Suppl. 1) 54
payment under fee schedule, (Suppl. 1) 62
reform, diabetes care reimbursement, 577
Menstrual cycle, glucose metabolism, 213
Metabolic control
lipoprotein(a) levels, 941, 1441
polymorphonuclear leukocyte function, 256
Metformin, 756
Mexiletine, neuropathy treatment, 1550
Microalbuminuria
bead assay,l 1451
blood pressure measurements, 1614
genetics, 1181
insulin-dependent diabetes mellitus, prevalence, 495
neuropathy, 528
plasma endothelin level, 1038
prevention of development from normoalbuminuria, 1216
screening, 1581
Miglitol
effects on starch content in food, 478
non-insulin-dependent diabetes mellitus therapy, 793
MODY. *See* Maturity-onset diabetes of the young
Molecular physiology, non-insulin-dependent diabetes mellitus, 369
Monoamine oxidase inhibitors, non-insulin-dependent diabetes mellitus therapy, 799
Mortality
hyperglycemia, relationship to coronary/cardiovascular, 1328
international comparisons, (Suppl. 1) 15
Pima Indians, non-insulin-dependent diabetes mellitus, 1541
risk factors, cardiorespiratory fitness, 184
Muscle
blood flow after exercise, 693
glucose transport, interaction of insulin and exercise, 1679
semimembranosus, microangiopathic ischemic myopathy, 586

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

skeletal
decreased insulin-induced glucose utilization, 1747
exercise effects on metabolism, 1701
insulin resistance, 418
soleus
catecholamines effects, 1716
glucose metabolism after exercise, 1694
Myocardial
infarction, 288
left ventricular pump remodeling, 1522
ischemia, 288

N

Navajo Indians, prevalence, impaired glucose tolerance, 114
Nephropathy
advanced glycosylation end products, 302
antihypertensive therapy, 918
end-stage patient, management of, 1226
glomerular filtration rate estimation, 609
glycemic control, 1126
insulin-dependent diabetes mellitus, erythrocyte spermidine levels, 543
prediction, blood pressure measurements, 1614
primary prevention, 1216
risk factors, 1192, 1205
Neuropathy, 1926
ADA consensus statement, (Suppl. 2) 62
autonomic, coronary artery disease, 288
capsaicin effects, 8, 159
on sensory function, 15
topical, improvement of symptoms, 1434
foot pressure, amputees, 905
glycemic control, 1126
measures, 1080
autonomic nervous system testing, 1095
clinical, 1081
electrodiagnostic, 1087
morphological and biochemical, 1084
quantitative sensory testing, 1092
mexiletine effects, 1550
microalbuninuria, 528
pathogenesis, 1902
study of predictors, 525
Nicotinamide, insulin-dependent diabetes mellitus remission, 121
NIDDM. *See* Non-insulin-dependent diabetes mellitus
Nitrate levels in drinking water, insulin-dependent diabetes mellitus risk factor, 1505
Non-insulin-dependent diabetes mellitus
β-cell dysfunction, 442
β-endorphin levels, 590
biguanides, 755
Black Americans, insulin action, 1295
blood pressure, insulin therapy effect, 1258
body fat distribution, 306
cardiovascular disease, 1141
children, prediction, 244
chronic renal failure, lipoprotein(a) levels, 976
combination therapy, 265
insulin and sulfonylurea, 953
C-peptide response to meal stimulus, 1335
diet
benefits of low-glycemic index, 562
high carbohydrate intake effects, 1572
miglitol effects on starch, 478
postprandial blood glucose levels, 522
dyslipidemia
effect on glycemic control, 508
prevalence, 1285
early-onset, glucokinase gene mutation, 1108
elderly, glyburide and glipizide effects, 75
exercise, 136
ADA technical review, (Suppl. 2) 50
atherosclerosis, effect on, 1787
interaction with insulin, 1777
prevention, 1704
genetics, 369
glucagonlike peptide I(7-37), 270
glucose
homeostasis, 371
metabolism, 373
transport, 396
glycemic control
dyslipidemia control, 638
insulin therapy effects, 27
management of, 1560
health status measurement, 469
hyperglycemia
high carbohydrate intake effects, 1572
overview, 331
hyperproinsulinemia, 723
hypertension, effect on glycemic control, 508
hypertriglyceridemia, 657
hypoglycemia
enalapril-induced, 934
fatty acid oxidation inhibitors, 773
insulin receptor
activity, 277
gene mutations, 590
insulin resistance
overview, 324, 337, 343
skeletal muscles, 418
insulin secretion
insulin action, 335
overview, 319
intracellular magnesium deficiency, 1825
leukocyte ROI generation, 1050
lipoproteins, gemfibrozil effects, 146
magnesium deficiency, 835
molecular physiology, 369
myocardial infarction, left ventricular pump remodeling, 1522
obesity
depression, 253
effect on glycemic control, 508
exercise, 1783
waist-hip ratio, 912
onset, 815
oral antiabetic agents, 1075
oral hypoglycemic agents, CS-045, 193
pathogenesis, 318, 351
amylin role, 297
pathophysiology, liver, 431
patient education, effect on weight reduction, 864
Pima Indians, mortality and causes of death, 1541
postprandial glycemia, 111
prediction, hyperinsulinemia, 241
prevention, exercise, 1794
proteinuria, dietary protein intake, 178
retinopathy
hypertension, 1002
increased plasma endothelin, 1396
Oklahoma Indians, 1620
risk factors
diet, 238
genetics, 237
obesity, 233
physical activity, 233
screening, sensory function, 847
secondary failure to sulfonylureas, alternative treatments, 539
sulfonylureas, 696, 737
therapy, 792
insulin and sulfonylurea, 831
refractory changes of eyes, 938
weight reduction, 926
Nutritional recommendations, ADA position statement, (Suppl. 2) 21

O

Obesity
depression, 253
family history of diabetes, 1455
insulin receptor activity, 277
non-insulin-dependent diabetes mellitus
Black Americans, insulin resistance, 1295
effect on glycemic control, 508
exercise, 1783
risk factor, 233
waist-hip ratio, 912
Oklahoma Indians, retinopathy incidence, 1620
Oral antidiabetic agents
dichloroacetate, 785
thiazolidinedione, 1075
Oral hypoglycemic agents, CS-045, 193
Osteomyelitis
leukocyte scanning superior to magnetic resonance imaging, 1527
scintigraphy detection, 1014

P

Pancreas
artificial, 303

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

transplantation, 1668
ADA position statement, 1673
quality of life, 305, 1459
Pancreatic disease, insulin-dependent diabetes mellitus, albumin excretion rate, 1591
Patient
education
diet, computer-assisted, 204
empowerment, 922
evaluation of, 1323
non-insulin-dependent diabetes mellitus, weight reduction, 864
reimbursement
quality, (Suppl. 1) 36
third-party, ADA position statement, (Suppl. 2) 41
standards, (Suppl. 2) 75
empowerment, 922
Peripheral nervous system, somatosensory conduction delay, 532
Phenytoin, topical, healing foot ulcers, 1433
Physical
activity
non-insulin-dependent diabetes mellitus risk factor, 233
proliferative retinopathy risk factor, 1267
fitness, mortality risk, 184
Pima Indians, non-insulin-dependent diabetes mellitus effects on mortality and causes of death, 1541
Plasma endothelin level, insulin-dependent diabetes mellitus, microalbuminuria, 1038
Platelet
aggregation, magnesium deficiency, 835
function increase, exercise effects, 1742
Polymorphonuclear leukocyte function, metabolic control, 256
Population growth implications on prevalence, (Suppl. 1) 6
Pregnancy
insulin-dependent diabetes mellitus, hypoglycemia incidence, 1034
insulin requirements in final month, 1323
macrosomia, glycemic control, 1251
normoglycemia/hypoglycemia, hemodynamic states, 939
oral glucose tolerance test, 1826, 1827
primary care physicians, 101
sonograms, 613
standards of care, financial implications, (Suppl. 1) 22
See also Gestational diabetes mellitus
Prevalence
Alaskan Eskimos and Indians, 1390
Brazil, 1509
carotid atherosclerosis, 1290
depression, obesity, 253
hyperglycemia, Saudi Arabia, 484
impaired glucose tolerance, Navajo Indians, 114
insulin-dependent diabetes mellitus
eating disorders, adolescent girls, 1361
Nigerian Igbo schoolchildren, 1310
microalbuminuria, 495
neuropathy, 1926
non-insulin-dependent diabetes mellitus
dyslipidemia, 1285
India, 1348
population growth implications, (Suppl. 1) 6
Pu-Li, Taiwan, 81
retinopathy, 1844
relationship with diabetes duration, 815
Primary care physicians, gestational diabetes mellitus, 101
Proinsulin
levels, insulin-dependent diabetes mellitus, first-degree relatives, 632
screening, insulin-producing tumors, 931
Proteinuria, dietary protein intake, 178
Psychosocial
factors, insulin-dependent diabetes mellitus, 166
problems and interventions, 1640

Q

Quality assurance, (Suppl. 1) 51

R

Relaxation training, thermal biofeedback-assisted, blood circulation, 853
Research, use of animals, ADA position statement, (Suppl. 2) 43
Retinopathy, 1844
biochemical basis, 1892
cell-cell interactions, 1168
community-based clinics, 144
glycemic control, 1126
insulin-dependent diabetes mellitus, erythrocyte spermidine levels, 543
incidence of endothelial cell antibodies, 552
non-insulin-dependent diabetes mellitus
increased plasma endothelin, 1396
Oklahoma Indians, incidence, 1620
prevalence of and relationship with diabetes duration, 815
proliferative, 1875
physical activity levels, 1267
risk factors, hypertension, 1002
screening
ADA position statement, (Suppl. 2) 16
cost-effectiveness, 580, 1369
standards, financial implications, (Suppl. 1) 32
treatment, interferon, 300
Risk factors
cardiovascular disease, 1141
albuminuria as marker, 1181
elevated fibrinogen, 1245
impaired glucose tolerance, 239
insulin resistance, 239
physical activity, 236
control of, 1818
insulin-dependent diabetes mellitus, nitrate in drinking water, 1505
nephropathy, 1192, 1205
mortality, cardiorespiratory fitness, 184
non-insulin-dependent diabetes mellitus, 232
proteinuria, dietary protein intake, 178
Pu-Li, Taiwan, 81
retinopathy
Oklahoma Indians, 1620
proliferative, physical activity, 1267

S

Sardinia, incidence of insulin-dependent diabetes mellitus, 1317
Saudi Arabia, hyperglycemia prevalence, 484
Screening
ADA position statement, (Suppl. 2) 7
gestational diabetes mellitus, prediction of birth weight, 1605
insulin-producing tumors, proinsulin, 931
lower-extremity amputation. 1386
microalbuminuria, 1581
prediabetes, diabetes camp, 1439
retinopathy
ADA position statement, (Suppl. 2) 16
cost effectiveness, 580, 1369
sensory function, non-insulin-dependent diabetes mellitus, 847
Self-care
dropout and relapse factors, 1477
insulin-dependent diabetes mellitus, children and adolescents, 43
Self-monitoring of blood glucose
ADA
consensus statement, (Suppl. 2) 56
position statement, (Suppl. 2) 38
families of children/adolescents, use of test results, 1041
home monitors, accuracy, 536
quality control, 1824
SMBG. *See* Self-monitoring of blood glucose
Smoking, insulin-dependent diabetes mellitus, morbidity, 947
Sorbinil, effect on limited joint mobility in insulin-dependent diabetes mellitus, 588
Standards of care
ADA position statement, (Suppl. 2) 10
eye disease, (Suppl. 1) 32
payment, (Suppl. 1) 10
pregnancy, financial implications, (Suppl. 1) 22
Stress, 1413, 1645
management
diabetic camp, 310
glycemic control, 842

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Sudan, insulin-dependent diabetes mellitus in children, 1556
Sulfonylureas
  insulin secretion, 738, 1534
  non-insulin-dependent diabetes mellitus, 737
  response in non-insulin-dependent diabetes mellitus, 696
  secondary failure, alternative treatments, 539
  therapy, combined with insulin, 746, 831, 953

T

Tanzania
  cassava toxicity, not cause of diabetes mellitus, 1378
  impaired glucose tolerance, 1114
Therapy. *See* Combination therapy; Insulin therapy
Thiazolidinedione, 1075
  derivates, non-insulin-dependent diabetes mellitus therapy, 794
Third-party payment
  origin of, (Suppl. 1) 10
  patient education programs, (Suppl. 1) 36, 41
    ADA position statement, (Suppl. 2) 41
Threshold, definitions/semantics, 1434, 1435
Transient neonatal diabetes mellitus, association with permanent diabetes, 1273
Transplantation, 1668, 1673
  kidney/pancreas, quality of life, 305, 1459
  management of patient, 1226
  pancreas-kidney, lipids, 35
Type I. *See* Insulin-dependent diabetes mellitus
Type II. *See* Non-insulin-dependent diabetes mellitus

U

Urinary insulinlike growth factor I, 490
Urine glucose/ketone tests, ADA position statement, (Suppl. 2) 38

V

Visual systems, contrast sensitivity thresholds, 620

W

Weight reduction
  effect of patient education, 864
  non-insulin-dependent diabetes mellitus, 926
Western Australia, incidence of insulin-dependent diabetes mellitus in children, 515
Wine, glycemic control, 546
Women
  greater effect of glycemia on hypertension, 1277
  insulin-dependent diabetes mellitus, menstrual cycle, 213

X

Xerostomia, 900

Y

Young adults, insulin-dependent diabetes mellitus, hyperglycemia effect on nerve conduction, 502

Z

Zinc insulin, fasting hyperglycemia, 173

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Author Index

A

Aarons, J.H., 613
Abadie, R.G., 204
Abildgaard, N., 1264
Abraira, C., 1560
Abrams, K.C., 43
Abu-Zeid, H.A.H., 484
Ackerman, S.J., 136, 580
Adamson, U.C.K., 59, 518
Afoke, A.O., 1310
Ahring, J.P.K., 971
Ahring, K.K., 971
Ainslie, M.B., 700
Airaksinen, K.E.J., 288
Aitchison, R.D., 588
Albergo, R., 1113
Alberti, K.G.M.M., 124, 1378
Albini, C.H., 490
Alford, F., 1053
Al-Kassab, A.S.K., 484
Allen, A.A., 1041
Allen, C., 502, 980
Altman, J.-J., 976
Alviggi, L., 543
American Diabetes Association, 1065, 1668, 1673
American Diabetes Association, Publications Policy Committee, 1059
Amorosa, L.F., 1800
Anderson, J.H., 666
Anderson, R.M., 859
Andreani, D., 1824
Andréasson, K., 59
Anfossi, G., 1742
Anton, J.-P., 204
Anyaoku, V., 306
Aoki, T.T., 469
Arkin, C.F., 1245
Arnqvist, H.J., 27
Arslanian, S., 928
Asal, N.R., 1620
Aubertin, J., 546
Auchincloss, H., Jr., 305

B

Baba, S., 128
Bachelot, I., 1614
Badger, G.B., 8, 15
Bailey, C.J., 755
Bailey, T.S., 265
Banerji, M.A., 1295
Banks, P., 300
Bantle, J.P., 1468, 1821
Barbosa, J.J., 121
Barnard, M.U., 43
Baron, A., 947
Baron, A.D., 309
Bartolomei, G., 543
Bayard, F., 204
Baynes, C., 306
Beck-Nielsen, H., 418
Becker, B.N., 586
Becker, D.J., 525, 559, 928
Beckwith, L.J., 1721
Beddok, R.H., 204
Beliveau, E., 141
Bell, D.S.H., 146, 528, 934, 936
Bellando, B.J., 43
Belsky, M.K., 1113
Bender, A.P., 1335
Benedetti, T.J., 1605
Bengtsson, C., 1455
Benhamou, P.Y., 1614
Benn, J.J., 1721
Bennert, H.W., (Suppl. 1) 22
Bennett, P.H., 1541
Berger, M., 1034, 1110, 1111, 1676
Berger, W., 632
Bessman, A.N., 1531
Bhatia, V., 582
Binder, C., 1009
Bingley, P.J., 1313
Bird, D.M., 1534
Bistoni, S., 1628
Björntorp, P.A., 1783
Blair, E.H., 253
Blair, S.N., 184
Blantz, R.C., 142
Bohannen, B., 571
Boizel, R., 1614
Boller, I., 1356
Bonadonna, R.C., 318
Bonen, A., 1694
Bonet, B., 1605
Bonner-Weir, S., 442
Bonneu, M., 204
Borch-Johnsen, K., 1181
Borchelt, M.D., 1449
Borland, K.M., 303
Boulton, A.J.M., 905, 1433, 1434
Bourgeois, M.J., 43
Bowbeer, M.A., 144
Bowsher, R.R., 666, 931
Boyko, E.J., 1390
Bradford, R.H., Jr., 1620
Bransome, E.D., Jr., (Suppl. 1) 1, 66
The Brazilian Cooperative Group on the Study of Diabetes Prevalence, 1509
Brechtel, G., 309
Bressler, R., 792
Brian, D., 140
Briani, G., 1595
Briet, E., 991
Britz, A., 583
Brodows, R.G., 75
Brouhard, B.H., 918, 928
Brown, A.W., 1477
Brown, J.B., 870
Brown, L.J., 895
Brown, M.D., 124
Brown, P.M., 1721
Brown, Z.A., 613
Brownlee, M., 1835
Brubaker, G.R., 1378
Buisson, J.-C., 204
Buithieu, M., 588
Bulkow, L.R., 1390
Bunt, T.J., 1598
Bunting, J., 1113
Burch, A., 1484
Burden, A.C., 1393
Burgoyne, W., 693
Burzacca, S., 1742
Buscema, M., 539
Bushhouse, S.A., 1335
Butler, S.N., 140
Buzzetti, R., 1824
Byrne, G.C., 515

C

Cai, Y., 947
Calabrese, G., 1628
Calderini, C., 1628
Camaré, R., 204
Cameron, D.P., 1534
Campbell, L.V., 221
Camuso, J., 305
Canafax, D.M., 121
Canani, L.H., 912
Canawati, H., 1531
Capsaicin Study Group, 159
Caputo, S., 620
Cardia, L., 1002
Cavalot, F., 1742
Cayatte, A.J., 1156
Cembrowski, G.S., 700
Cerami, A., 302
Cerasi, E., 645
Cha, T., 1517
Chambless, L., 912
Chan, A.Y.W., 988
Chanson, P., 976

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Chantelau, E., 1727
Charles, M.A., 53
Chase, H.P., 95, 108, 1303
Chase, P.H., 140
Chen, H.-H., 81
Chick, W.L., 303
Childs, B., 1494
Chisholm, D.J., 221
Chiumello, G., 651
Chou, P., 81
Chrisment, C.Y., 204
Cignarelli, M., 1002
Clare-Salzler, M.J., 132, 1273
Clark, C.M., Jr., 101, (Suppl. 1) 10
Clarke, W.L., 43
Clasen, B.L., 700
Clements, C.A., 536
Clements, R.S., Jr., 723
Clemow, L., 1800
Clottes, J.P., 204
Clouse, R.E., 1631
Cocchi, M., 111
Cockram, C.S., 988
Cocozza, S., 591
Cohen, R.M., 723
Colca, J.R., 1075
Colen, L.B., 1926
Collier, A., 1038
Collins, R.C., 142
Colman, P.G., 1053, 1313
Colwell, J., 1560
Combs, C.A., 1251
Compton, P.J., 221
Comstock, J., 1560
Consoli, A., 430
Consoli, G., 1438
Coscelli, C., 1628
Cosimi, A.B., 305
Costa, R., 265
Coustan, D.R., 716, (Suppl. 1) 22
Craven, J.L., 90
Crepaldi, G., 1591
Crespin, S.R., 1068
Crowley, L.E., 1045, 1494
Cruickshanks, K.J., 108, 947, 1267, 1303
Cryer, P.E., 1435
Culler, F.L., 1439

D

D'Alessio, D.J., 502, 980
Damato, A., 1002
D'Ambrosio, M., 1591
D'Amore, P.A., 1168
Damsbo, P., 418
Damsgaard, E.M., 1192
Dandona, P., 693
Daneman, D., 90, 1402
Dannehl, K., 908
Darlow, B.A., 895
Daskalova, I.K., 930
Daughtry, S.B., 549
Davidson, J.K., 702
Davidson, M.B., 719
Davidson, P., 1477
Davis, M.D., 1844
Davis, S.N., 124
Davis, W.K., 859
The DCCT Research Group, 886
Deam, D., 1053
DeBerry, K., (Suppl. 1) 15
De Cicco, M.L., 1002
Deckert, T., 1181
De Facis, R., 1742
DeFronzo, R.A., 317, 318, 1125
De Gaudemaris, R., 1614
De Giorgio, L.A., 543
Dela, F., 1712
Delaney, V., 302
Delcher, H.K., 1439
Delecki, A., 1034
Della Cassa, L., 645
Delmonico, F.L., 305
Del Rio, G., 645
De Meyts, P., 702
Demura, H., 1396
De Pergola, G., 1002
D'Eramo-Melkus, G.A., 864
DeStefano, F., 960
Devlin, J.T., 1690
Dharmaraj, D., 1348
Diamond, M.P., 213
Diem, P., 585
Di Leo, M.A.S., 620
Dimitrakoudis, D., 1747
Dodge, A.B., 1168
Donahue, R.P., 1141
Donnelly, M.B., 859
D'Onofrio, F., 1, 1438
Dooijewaard, G., 991
Doolman, R., 1451
Dorman, J.S., 559, 626
Dørup, J., 522
Dosio, F., 651
Dotta, F., 1824
Dozio, N., 651
Drash, A.L., 127, 525, 559, 626, 928
Driscoll, C., 141
Drury, P.L., 609
Duck, S.C., 502, 980
Duckworth, W.C., 35, 567
Duncan, B.B., 912
Dunger, D., 1356
Dunn, F.L., 877, 1581

E

Egger, M., 585
Eggstein, M., 261
Eisenbarth, G.S., 1313
Ejeh, N.M., 1310
Ekoe, J.-M., 1464
Ekstrand, A., 831
Elamin, A., 1556
Elbein, S.C., 1285
Elixhauser, A., (Suppl. 1) 22
Elkeles, R.S., 306
Ellis, D., 525
Emanuele, N., 1560
Epstein, S.F., 141
Eriksson, J.G., 831
Eshøj, O., 1585

F

Fairburn, C.G., 1356
Fallon, J.J., Jr., 1113
Falsini, B., 620
Farebrother, M., 1721
Farid, N.R., 971
Farkas-Hirsch, R., 593
Farreny, H., 204
Fazio, F., 651
Fedele, D., 1628
Federlin, K., 256, 1550
Feinglos, M.N., 590, 933, 1413, 1581
Feldman, E.L., 1902
Feldt-Rasmussen, B., 1181
Fenato, R., 1591
Ferrannini, E., 318, 508
Ferrara, A., 591
Feste, C., 922
Fineberg, N.S., 702, 1031, 1045
Fineberg, S.E., 702, 1045
Fioretto, P., 1591
Fisher, R., 1494
Fleminger, G., 1451
Fogel, H., 270, 305
Foley, J.E., 773
Fonseca, V.A., 693
Forbes, L.V., 895
Ford, E.S., 960
Francis, S.J., 1449
Franco, L.J., 1509
Franconi, F., 543
Frank, B.H., 666
Franssila-Kallunki, A., 831
Franz, M., 571
French, L.R., 1335
Frick, M.H., 820
Friedberg, S.J., 953
Friedman, E.A., 302, 1226
Frier, B.M., 552
Fries, T.J., 8, 15
Fyhrquist, F., 1736

G

Gabbe, S.G., (Suppl. 1) 22
Galbo, H., 1712
Gale, E.A.M., 1313
Gale, S.M., 947
Galimberti, G., 651

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Gallen, I.W., 1826
Galloway, J.A., 666, 702
Galvan, A.Q., 508
Gambardella, A., 1
Ganda, O.P., 1245
Garber, A.J., 1068
Garg, A., 1572
Garg, S.K., 140
Gargantini, L., 651
Garvey, W.T., 396
Gavard, J.A., 559, 1631
Gavin, L.A., 1251
Gay, E.C., 95, 108, 947, 1303, 1505
Gebhart, S.S.P., 1439
Geffner, D.L., (Suppl. 1) 44
Geffner, M.E., 1273
Geiger, P.J., 1531
Geisser, M.S., 1335
Georgopoulos, A., 19
German, R.R., 960
Gerundini, P.G., 651
Ghirlanda, G., 620
Giacca, A., 1747
Gibson, R., 1045
Gilbert, T.J., 114
Gillespie, S.M., 1264
Gin, H., 546
Giorgino, R., 1002
Gironi, A., 543
Giugliano, D., 1, 1438
Glaser, B., 645
Glasgow, A.M., 141
Glasgow, R.E., 1423
Glauber, H.S., 870
Gloninger, M., 626
Goetz, F.C., 1335
Gohdes, D.M., 1386
Goldberg, R.B., 847
Golden, M.P., 1031
Golichowski, A., 101
Gordon, A., 645
Gordon, N.F., 184
Goslen, J.B., 1598
Gottschalk, M.E., 1273
Gower, I.F., 1464
Graber, A.L., 1477
Grace, A.A., 693
Granner, D.K., 369
Greco, A.V., 620
Green, A., 900
Greene, D.A., 525, 1902
Greene, Y.J., 785
Gregersen, S., 522
Greulich, B., 66
Gries, F.A., 908
Griffith, L.S., 1631
Griffiths, S.M., 931
Groop, L.C., 737, 831
Gross, J., 645
Grunberger, G., 696
Grundy, S.M., 1572
Guare, J., 253
Guillausseau, P.-J., 976
Gumbiner, B., 193
Gunderson, E., 1251
Guthrie, R., 1494

H

Habener, J.F., 270, 1441
Haffner, S.M., 508, 638, 1277
Hagan, J.A., 864
Hagen, C., 1585
Haig, B., 700
Halimi, S., 1614
Hamman, R.F., 95, 108, 947, 1303, 1505
Hammond, G.S., 469
Handa, N., 1290
Handberg, A., 418
Hansen, K.W., 1192
Harman-Bohem, I., 968
Harper, P.N., 1811
Harrelson, J.M., 586
Harrington, E., 1527
Harrington, M., 1527
Harris, M.I., 815
Harrison, L.C., 1053
Hart, L.K., 1459
Hartling, S.G., 632
Hauser, T., 221
Hazuda, H.P., 638, 1277
Heere, L.P., 991
Heesen, B.-J., 941
Heinemann, L., 718, 1034
Heinonen, O.P., 820
Hellman, R., 1494
Helms, R.B., (Suppl. 1) 6
Henderson, A.D., 306
Henderson, W., 1560
Henriksen, J.E., 418
Henriksson, J., 1701
Herman, W., (Suppl. 1) 22
Hermann, G., 1527
Hermansen, K., 522
Heshka, S., 265
Hespel, P., 1767
Hiar, C.E., 1045, 1494
Hirsch, I.B., 593
Hiss, R.G., 144
Hofmann, C.A., 1075
Holland, M.T., 1926
Hollis, C.R., 933
Holloway, G.A., 1598
Holst, J.J., 1440
Homa-Lowry, J., (Suppl. 1) 51
Hooper, S.A., 666
Hori, S., 1396
Horton, E.S., 1676
Hosoda, Y., 532
Hostetter, T.H., 1205
Hougaku, H., 1290
Hough, B.S., 1041
Howey, D.C., 666
Howlett, W.P., 1378
Hsiao, K.-J., 81
Hunt, S.C., 1285
Huth, E.J., 1062
Huttunen, J.K., 820
Hylton, H., 1464

I

Iavicoli, M., 173
Ignesti, G., 543
Ikegami, H., 1517
Imai, T., 938
Implantable Insulin Pump Trial Study Group, 877
Inada, M., 1522
Inoue, Y., 937
Iovine, C., 173
Ipp, E., 931
Ireland, P., 1499
Italia, S., 539
Iwasaka, T., 1522
Iwasaki, N., 1396

J

Jackson, R.A., 1313
Jacobs, D.R., Jr., 1335
Jacobson, A.M., 1398
Jacobson, J., 1369
Jakober, B., 261
Jameel, N., 178
James, D.E., 1679
James, I.M., 693
Jardine, A., 1038
Jauhiainen, M., 657
Jawad, A., 253
Jean-Didier, N., 53
Jelliffe, K.A., 588
Jenkins, A.L., 562
Jenkins, D.J.A., 562
Jensen, T., 1181
Joffe, B.I., 277, 556
Johnson, D., 792
Johnson, N.B., 1031
Johnson, S.B., 1658
Johnston, D.G., 306
Jones, D.B., 552
Jorgensen, J.O.L., 1264
Jori, E., 1591
Josse, R.G., 562
Jovanovic-Peterson, L., 613
Joyce, C., 971

K

Kamada, T., 1112, 1290
Kamakura, K., 532
Kamper, K., 718

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Kanda, T., 1112
Kapadia, A.S., 1369
Karohl, C., 912
Kato, M., 847
Kaufman, D.L., 132, 1273
Kaufmann, R.C., (Suppl. 1) 22
Kawaguchi, Y., 1517
Kawamori, R., 1112, 1290
Kawamura, M., 1396
Kean, J., 1053
Kelley, J.L., 1156
Kelly, H.A., 515
Kelsey, S.F., 559
Kemmer, F.W., 1676, 1732
Ketchum, C.H., 528
Khachadurian, A.K., 1800
Kiens, B., 1767
Kilo, C., 1494
Kimmerle, R., 1034
Kimura, Y., 1522
King, H., 1114, 1794
Kinghorn, H.A., 1824
Kingma, P.J., 478
Kingsley, R.M., 1620
Kinney, E.D., (Suppl. 1) 10
Kirsch, C.-M., 1014
Kitange, H.M., 1378
Kitzmiller, J.L., 1251, (Suppl. 1) 22
Kjær, K., 1585
Klein, B.E.K., 282, 1267, 1875
Klein, M.J., 1527
Klein, R., 282, 815, 980, 1267, 1875
Klingensmith, G.J., 95, 108, 140, 1303
Klip, A., 1747
Kluft, C., 991
Knopp, R.H., 613, 1605
Knowler, W.C., 1541
Knuiman, M.W., 815
Kobayashi, I., 1050
Kobayashi, T., 1435
Koffler, M., 1572
Kofoed-Enevoldsen, A., 1181
Kohl, H.W., 184
Koistinen, M.J., 288
Koivisto, V.A., 1736
Kolb, E.L, 826
Kollind, M.E., 59
Korhonen, H.J., 657
Korn, A.M., (Suppl. 1) 59
Kosaka, K., 1435
Koschmann, M., 1053
Koskinen, P., 820
Kostraba, J.N., 95, 559, 626, 947, 1303, 1505
Kraegen, E.W., 221
Kremer, R.M., 1449
Kriska, A.M., 1794
Kronz, K.K., 1031
Kruseman, A.C.N., 478, 941
Krusinski, P.B., 8
Kuller, L.H., 525
Kumar, S., 1433
Kunze, W., 718

L

Laakso, M., 1020
Laine, D.C., 1468
Lairson, D.R., 1369
Laker, M.F., 1264
Lalla, D., 997
Langefeld, C.D., 101
Lanier, A.P., 1390
Lapidus, L., 1455
Lapolla, A., 1628
LaPorte, R.E., 128, 559, 626, 1464, (Suppl. 1) 15
Larsen, J.L., 35
Lasker, R.D., (Suppl. 1) 62
Lassen, L.H., 1009
Lattimer, S.A., 1902
Lau, J.T.F., 988
Lave, L.B., 1464
Lawler-Heavner, J., 1303
Leach, J.P., 1038
Leahy, J.L., 442
Le Beau, J.M., 1926
Lebovitz, H.E., 1295
Lee, E.T., 1620
Lee, V.S., 1620
Legrand, A., 976
Leinsinger, G., 1014
Levin, S., 1560
Levy, R.P., 1449
Lewis, C.M., 121
Lewis, G.A., 8, 15
Librenti, M.C., 111
Lindström, T.H., 27
Lingenfelser, T., 261
Lins, P.-E. S., 59, 518
Lissner, L., 1455
Littlefield, C.H., 90
Litton, J.C., 310
Liu, D., 59
Liuzzi, F.J., 1926
Lloyd, C.E., 166
Long, S.D., 549
Lorimor, R.J., 1369
Lozano, J.L., 53
Lu, M., 1620
Lubetzki, J., 976
Lucchina, P.G., 1742
Ludvigsson, J., 1310
Luong, H., 835
Luskey, K.L., 297
Lustman, P.J., 1631
Lyko, K., 1441

M

Ma, A., 1534
MacGillivray, M.H., 490
Maeda, H., 1290
Maeser, E., 256
Magee, M.S., 1605
Mahon, J., 66
Mahoney, M.D., 303
Main, E.K., 1251
Maislos, M., 968
Maki, T., 303
Makita, Z., 302
Malayan, S., 835
Malerbi, D.A., 1509
Mallion, J.M., 1614
Malone, J.M., 1598
Mammini, P., 543
Mandarino, L.J., 1892
Mandrup-Poulsen, T., 66
Manninen, V., 820
Manoharan, G., 1433
Mänttäri, M., 820
Marcus, M.D., 253
Marette, A., 1747
Marhoffer, W., 256
Markell, M.S., 1226
Marks, J.S., (Suppl. 1) 22
Marrero, D.G., 101, 1045
Martin, S., 66
Martini, P.F., 204
Marx, G.F., 939
Maser, R.E., 525
Massucco, P., 1742
Matsuda, M., 938
Matsui, Y., 1522
Matsumoto, H., 937
Matsumoto, M., 1290
Matsushima, H., 1290
Matthews, K.A., 166
Mattiello, L., 1742
Matz, R., 1825
Mauri, M.G., 1628
Maxwell, T.M., 1285
Mazzarino, S., 539
McCaskill, C.C., 590
McCulloch, D.K., 1313
McDermott, J.C., 1694
McGill, J.B., 593
McIntyre, H.D., 1534
Mclarty, D.G., 1378
McLellan, A., 1038
McManus, R.M., 1323
McMurry, J.F., Jr., 842
McNeill, D.B., 586
McRae, J.R., 1477
Meacham, L.R., 1439
Megeney, L.A., 1694
Meinders, A.E., 991
Meinhold, P.A., 43
Menheere, P.P.C.A., 478, 941
Menon, R.K., 693
Metzger, B.E., 613
Meyer, U.E., 1550
Mezitis, N.H.E., 265
Micossi, P., 111, 651, 877
Microalbuminuria Collaborative Study Group, 495
Mikines, K.J., 1712
Milde, F.K., 1459
Miller, S.A., 35
Mills, B.J., 490
Mills, J.L., 613

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Minamori, Y., 1437
Minnella, A., 620
Mitchell, B.D., 178, 508, 638, 1277
Mlingi, N., 1378
Moberg, E.A.R., 59
Mogensen, C.E., 1192
Mojsov, S., 270
Molitch, M.E., 1826
Moller, J., 1264
Moller, N., 1264
Monaco, A.P., 303
Monticelli, A., 591
Moore, M.P., 895
Moore, P., 101
Morales, P.A., 1277
Mori, M., 1050
Morlat, P., 546
Morocutti, A., 1216
Morris, M.A., 310
Morton, J.J., 1038
Moss, S.E., 282, 1267, 1875
Motala, A.A., 1258
Mtinangi, B.L., 1378
Mühlen, H., 908
Mühlhauser, I., 1110, 1111
Mularoni, E., 1742
Muller, T.E., 303
Muntoni, S., 1317
Mura, A., 173
Murase, T., 1435
Murgai, N., 1041
Murphy, N.J., 1390
Murray, M.A., 90
Muthukumarsamy, M.G., 1433
Mykkänen, L., 1020

N

Nadler, J.L., 835
Nagata, N., 532
Nakamura, R., 532
Nakamura, S., 1522
Nakanishi, K., 1435
Nankervis, A., 1499
Nao, K., 1290
Naruse, K., 1396
Naruse, M., 1396
Natarajan, R.D., 835
Nathan, D.M., 270, 305, 723, 877, 1441
National Institute of Child Health and Human Development in Early Pregnancy Study, 613
Naylor, C.D., 1827
Nelson, R.G., 1541
Neville, T.G., 1303
Newman, J.M., 960
Newman, L.G., 1527
Newsholme, E.A., 1716
N'Guyen, M., 976
Nicholson, T.J., 1361
Nielson, O.H., 418
Nikitin, Y., 915
Nishizawa, H., 1290
Nolan, J.J., 193
Nørgaard, K., 1181
Noritake, M., 532
Norman, D., 305
Norris, L., 140
Nosadini, R., 1591
November, M.T., 310
Nuttall, F., 571, 1560
Nwonu, E.N., 1310

O

Oberholzer, M., 632
O'Brien, K.F., 549
O'Brien, R.M., 369
O'Connor, C.A., 1449
O'Dea, K., 1499
Oestreich, P.G., 1335
Ogata, E.S., (Suppl. 1) 22
Ogihara, T., 1517
Ohgawara, H., 1396
Ohki, Y., 928
Okafor, C.O., 1310
Okubo, N., 1522
Olefsky, J.M., 193
Olson, D.R., 960
O'Malley, B.C., (Suppl. 1) 54
Omar, M.A.K., 1258
Omer, M.I.A., 1556
Omori, Y., 937, 1396
Orchard, T.J., 166, 525, 559, 1141
Orsi, E., 111
Ørskov, C., 1440
Osteen, V.L., 1423
Østerby, R., 1192
O'Sullivan, J.B., 1826
Otley, C.C., 586
Ovesen, P.G., 1264
Owens, D.R., 1484
Ozaki, C.F., 35

P

Pagliarini, S., 1002
Palestro, C.J., 1527
Palta, M., 980
Panz, V.R., 277, 556
Paolisso, G., 1
Parillo, M., 173
Paternostro, A., 1002
Patterson, C.A., 1534
Pawlowski, B., 66
Peak, M., 124
Pelkonen, R., 1736
Penttila, I., 657
Peters, A.L., 719
Peters, J.R., 1484
Peveler, R.C., 1356
Peynet, J., 976
Peyrot, M.F., 842, 1640
Pianese, L., 591
Pinson, M.B., 1494
Piper, R.C., 1679
Pisu, E., 1628
Pi-Sunyer, F.X., 265
Pitiot, M., 1614
Pitkanen, M., 657
Pizza, G., 1
Plonz, C., 261
Podar, T., 915
Porcellini, A., 591
Porciatti, V., 620
Potter van Loon, B.-J., 991
Poupon, J., 976
Poussier, P., 997
Pozza, G., 111, 651
Pozzilli, P., 1824
Price, D.E., 1393
Pugh, J.A., 178, 953, 1369
Pyörälä, K., 1020

Q

Quatraro, A., 1438
Quattrin, T., 490

R

Raal, F.J., 277, 556
Rabuazzo, A.M., 539
Raccah, D., 53
Radjaipour, M., 261
Radoff, S., 302
Ragnaud, J.M., 546
Ramachandran, A., 1348
Ramirez, G., 953
Ramlal, T., 1747
Rand, L.I., (Suppl. 1) 32
Randeree, H.A., 1258
Rao, R.H., 721
Raskin, P., 1126
Rasmussen, O.W., 522
Ratner, R.E., 565, 1814
Rayfield, E.J., 302
Reaven, G.M., 1057
Reed, G.F., 613
Reiber, G.E., (Suppl. 1) 29
Reichard, P., 583
Reiter, E.O., 490
Renn, W., 261
Rewers, M., 95, 1505
Riccardi, G., 173, 591
Rice, B.I., 853
Richmond, W., 306
Richter, E.A., 1767
Richter, W.O., 1014, 1441
Riley, W.J., 1313

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Rith-Najarian, S.J., 1386
Ritter, M.M., 1014, 1441
Riva, F., 1591
Rivellese, A.A., 173
Roberts, S.S., 137, 926, 1108
Robinson, C.A., 528
Rodin, G.M., 90, 1402
Rodnick, K.J., 1679
Roll, H.M., 518
Roman, S.H., 1527
Rosenbloom, A.L., 588
Rosenqvist, U., 583
Rosling, H., 1378
Ross, S.L., 590
Rossi, A., 1628
Rousselet, F., 976
Rozek, M.M., 1156
Rubin, R.R., 1640
Rude, R.K., 835
Ruderman, N.B., 1676, 1787, 1800
Ruskey, C.T., 140
Russell, D., 1620
Russell, P.S., 305
Ruth, K.J., 1328
Ryan, E.A., 1323
Rydall, A.C., 90

S

Saitas, V., 265
Sakiewicz, L.A., 933
Salomaa, V.V., 657
Saloranta, C., 831
Sammut, C., 221
Sampson, M.J., 609
Sanders, P.U., 939
Sandø, S.H., 1585
Sane, T., 1736
Sangiorgio, L., 539
Santoro, S., 1002
Sardinian Collaborative Group for Epidemiology of IDDM, 1317
Sartori, S., 651
Sato, N., 1050
Saudek, C.D., 19, 567
Sauder, S.E., 826
Savi, A., 651
Sawin, C., 1560
Sawyer, J., 953
Scaldaferri, E., 1591
Schachner, S.H., 1115
Schalin-Jäntti, C., 831
Scharf, D.R., 549
Schatz, D.A., 1273
Scheer, K., 613
Schiffrin, A., 997
Schindler, J.V., 853
Schmidt, M.I., 912
Schneider, M.S., 1413
Schneider, S.H., 1787, 1800
Schraer, C.D., 1390
Schreiber, E., 270
Schumacher, H.E., 1550
Schumacher, M.C., 1285
Schwab, S.J., 1581
Schwandt, P., 1014, 1441
Schwartz, C.J., 1156
Schwartz, F., 1451
Schwartz, M., 1527
Scott, F.W., 626
Scott, R.S., 895
Seedat, M.A., 1258
Seftel, H.C., 277, 556
Seghieri, G., 543
Sela, B.-A., 1451
Selam, J.-L., 53, 877
Sels, J.-P.J.E., 478, 941
Sepe, S.J., 960, (Suppl. 1) 22
Sgnaolin, E., 1591
Shaw, S., 835
Shi, Z.Q., 1747
Shibasaki, H., 532
Shimizu, H., 1050
Shimomura, Y., 1050
Shubnikov, E., 915
Siche, J.P., 1614
Sievers, M.L., 1541
Sima, A.A.F., 1902
Siminerio, L.M., 1401
Simonson, D.C., 213
Simpson, J.L., 613
Sivakumar, G., 1433
Skolnik, E., 302
Slot, J.W., 1679
Small, M., 1038
Smith, G.D., 585
Smith, U., 1455
Snehalatha, C., 1348
Snorgaard, O., 632, 1009
Sodoyez, J.-C., 651
Sodoyez-Goffaux, F., 651
Sogari, F., 1438
Solomon, B., 1451
Solomon, B.A., 303
Songer, T.J., 1464, (Suppl. 1) 15
Songini, M., 1317
Sönksen, P.H., 1721
Sosenko, J.M., 847
Soto, R., 847
Soulé-Dupuy, C., 204
Spencer, M.L., 700
Spinas, G.A., 632
Spradlin, C.T., 666
Sprafka, J.M., 121
Sprague, E.A., 1156
Spüler, M., 908
Squatrito, S., 539
Sreebny, L.M., 900
Stabler, B., 310
Stacpoole, P.W., 785
Stagnaro-Green, A., 1527
Stamler, J., 1328
Stansberry, K.B., 1926
Steed, D.L., 1598
Steenkiste, A.R., 626
Stein, M., 256
Stengård, J., 657
Stephens, T., 577
Stephenson, J., 1110
Stepien, C.J., 144
Stern, M.P., 178, 508, 638, 1277
Stevens, M.J., 1902
Stevenson, J.M., 960
Stewart, V., 1053
Stolusky, T., 1386
Stracke, H., 1550
Stratta, R.J., 35
Striegel-Moore, R.H., 1361
Strowig, S., 1126
Sufit, R.L., 502
Sugarman, J.R., 114
Sugiura, T., 1522
Suissa, S., 997
Sullivan, S.J., 303
Surawicz, T.S., 282
Surwit, R.S., 590, 1413
Suter, S.L., 193
Suttner, A., 1494
Suwa, K., 1050
Suzuki, N., 1396
Swai, A.B.M., 1378
Swaminathan, R., 988
Swanson, J.E., 1468
Swick, H.M., 502

T

Tahara, Y., 1517
Takahashi, N., 1522
Takeda, N., 1437
Tamborlane, W.V., 1361, 1434
Tan, M.H., 1694
Tanaka, A., 1437
Tandan, R., 8, 15
Taniguchi, H., 1522
Tarris, R.H., 931
Tarumi, N., 1522
Tasaka, Y., 937
Tatala, S., 1378
Tate, P.F., 536
Tauber, J.-P.J., 204
Taylor, R.J., 35
Terlecki, M.E., 931
Tesauro, P., 1
Teuscher, A., 585
Theorell, P.G.T., 518
Thomas, N.L., 1464
Thomas, W., 1468
Thompson, C.J., 124
Thurm, U., 1811
Thye-Rønn, P., 418
Tian, R., 1264
Tiengo, A., 1591
Ting, G.S.P., 1273
Tobin, A.J., 132
Tobin, C.T., (Suppl. 1) 41
Tolkoff-Rubin, N., 305
Trevisan, R., 1591
Trischitta, V., 539

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985

Trovati, M., 1742
Trucco, M.M., 559, 705
Truglia, J.A., 588
Tucker, B.J., 142
Tuley, M., 953
Tuomilehto, J., 657, 915, (Suppl. 1) 15
Turcotte, L., 1767
Turek, J., 141
Turnin, M.-C.G., 204
Tuvemo, T., 1556
Tynan, W.D., 141
Tzanev, A.N., 930

U

Udeh, N.J., 1310
Uusitupa, M., 657

V

VA CS Group (CSDM), 1560
Vaag, A., 418
Vacarro, O., 1328
Valdez, R., 1277
Valdini, A., 900
Valente, A.J., 1156
Van Allen, M.I., 613
Vandagriff, J.L., 1045
Van Ross, E.R.E., 905
Varricchio, M., 1
Varrone, S., 591
Velez, R., 1369
Veterans Affairs Study Group, 567
Veves, A., 905, 1434
Viberti, G., 1216
Vigneri, R., 539
Villegas, J.A., 184
Vinicor, F., 960
Vinik, A.I., 1068, 1926
Viswanathan, M., 1348
Vittori, C., 1494
Vlassara, H., 302
von Linstow, M., 1712
Von Schenck, H.H., 27
Vora, J.P., 1484
Voss, E.M., 700
Vranic, M., 1747
Vuksan, V., 562

W

Wagenknecht, L.E., 146, 528
Wagner, M.L., 953
Wakelee-Lynch, J., 300
Wald, M., 645
Walden, C.E., 1605
Wallace, P., 193
Wallace, R., 552
Wallberg-Henriksson, H., 1777
Waller, J., 1527
Walters, J.E., 536
Ward, G., 1053
Ward, K.M., 1041
Warren-Boulton, E., (Suppl. 1) 36
Warshaw, H., 571
Watarai, T., 1112
Waxman, K., 53
Webster, M.W., 1598
Weintraub, I.D., 586
Weir, G.C., 442
Weiss, N.S., 114
Weissberg-Benchell, J., 141
Weitzman, S., 968
Weitzner, G., 997
Welborn, T.A., 815
Weschler, J.M., (Suppl. 1) 22
Wetterhall, S.F., 960
Wheeler, M.L., 571, (Suppl. 1) 36
Whitehouse, F., 1818
Widén, E., 831
Widom, B., 213
Wilkinson, C.P., 1620
Will, J.C., 960
Williams, B.T., 528
Williams, R.R., 1285
Wing, J.R., 277, 556
Wing, R.R., 166, 253, 293
Wirth, R., 1727
Wise, J.E., 826
Wolever, T.M.S., 562, 1436
Wolffenbuttel, B.H.R., 941
Wolfsdorf, J.I., 582
Wong, G.S., 562
Woo, J., 988
Wooldridge, K., 1477
Wredling, R.A.M., 518
Wu, L.L., 1285
Wylie-Rosett, J., 864
Wysocki, T., 43, 1041

Y

Yamamoto, Y., 1517
Yamasaki, Y., 1112, 1290
Yamato, E., 1517
Yammoto, M., 1437
Yang, Z., 302
Yasuda, K., 1437
Yip-Messent, J., 1216
Yoneda, H., 1517
Yu, A., 900

Z

Zaccaro, D.J., 980
Zappella, A., 1628
Zehr, P.S., 1459
Zein, K., 1556
Zhou, D.B., 931
Ziegler, A.G., 66
Ziegler, D., 908
Ziegler, M.G., 142
Zimmet, P.Z., 232

DIABETES CARE: VOLUME 15 (1992) PAGE NUMBERS BY ISSUE

January, 1–157
February, 159–315
March, 317–467
April, 469–607
May, 609–735
June, 737–814
July, 815–946
August, 947–1124
September, 1125–1244
October, 1245–1448
November, 1449–1833
December, 1835–1985